Last reviewed · How we verify
L Carnitine ( low dose)
L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production.
L-Carnitine facilitates the transport of long-chain fatty acids into mitochondria for β-oxidation, enhancing cellular energy production. Used for Primary carnitine deficiency, Secondary carnitine deficiency (chronic kidney disease, dialysis patients), Fatigue and muscle weakness associated with carnitine deficiency.
At a glance
| Generic name | L Carnitine ( low dose) |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Amino acid supplement / Metabolic agent |
| Target | Carnitine palmitoyltransferase (CPT) system |
| Modality | Small molecule |
| Therapeutic area | Metabolic / Nutritional / Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
L-Carnitine is an amino acid derivative that acts as a carrier molecule, binding to fatty acyl-CoA and transporting them across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system. This process is essential for aerobic metabolism of fatty acids and ATP generation. Low-dose L-Carnitine supplementation is used to support energy metabolism, particularly in conditions of carnitine deficiency or impaired fatty acid oxidation.
Approved indications
- Primary carnitine deficiency
- Secondary carnitine deficiency (chronic kidney disease, dialysis patients)
- Fatigue and muscle weakness associated with carnitine deficiency
- Supportive therapy in cardiovascular conditions
Common side effects
- Gastrointestinal upset (nausea, diarrhea, abdominal discomfort)
- Fishy body odor (trimethylaminuria-like)
- Muscle weakness or myalgia (rare)
Key clinical trials
- Effects of Carnitine Supplementation on Exercise-Induced Muscle Damage: A Randomized Controlled Trial (NA)
- Assessment of the Efficacy of Carnipure® AAS on Body Composition, Muscle Thickness, and Strength Adaptations in Healthy Men (NA)
- High-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure. (PHASE4)
- Carnitine Supplementation in Type 2 Diabetic Patients (NA)
- Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma (PHASE2)
- Oxidative Stress In Semen And Male Infertility (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L Carnitine ( low dose) CI brief — competitive landscape report
- L Carnitine ( low dose) updates RSS · CI watch RSS
- Ain Shams University portfolio CI